TB CLIPS, 내손안에 결핵정보. 폐와 결핵균 그래픽이 있는 뉴스레터 머리글.

편집자 한마디!

국내외 결핵(TB)뉴스

학술연구자료

STOP - TB 코리아 소식

㈜레고켐 바이오사이언스가 MDR-TB를 적응증으로 개발중인 Oxazolidinone계열의 `Delpazlolid`(LCB01-0371)에 대한 EBA연구 결과가 Antimicrobial Agents and Chemot
herapy에 발표 되었습니다.대부분의 EBA연구가 환자 등록 측면에서 남아프리카 공화국에서 수행되는데, 이번 Delpazolid EBA는 국내에서 시행된 첫 EBA로서 의미가 크다고 할 수 있겠습니다. 연구 시작에서 논문화까지 참여하신 선생님들의 노고와 열정으로 이루어 낸 국내 결핵연구의 쾌거로 생각되며, 앞으로 Linezolid를 대체할 수 있는 보다 안전한 약물로의 공헌을 기대해 봅니다.

Following the publication in 2021 of the Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance, the World Health Organization (WHO) is now in the process of updating the catalogue to accommodate additional evidence of resistance linked to genotype. Therefore, WHO issued a public call with a deadline 31 May 2022, appealing to national TB programs, public health bodies, industry, researchers and other agencies to provide suitable datasets. For further details, click here.

To better understand the extent of essential health service disruptions caused by the COVID-19 pandemic, the World Health Organization (WHO) has conducted three rounds of the Global pulse survey on continuity of essential health services during the COVID-19 pandemic. Ongoing disruptions have been reported have been reported in over 90% of countries surveyed in the third round of the survey, conducted during the period November-December 2021. Countries reported disruptions across services for all major health areas, including TB.

It’s been announced that the next Union World Conference on Lung Health will take place, virtually, from 08-11 November, addressing the theme of ‘Combating Pandemics: Today & Tomorrow’.

At least $18 billion is needed to get the fight against TB, malaria, and AIDS back on track from disruptions caused by the COVID-19 pandemic, the Global Fund says.

The Stop TB Partnership says discrimination and stigma is holding back tackling TB.

Reasons are given for the reported slow roll-out of a shorter regimen to treat drug-resistant TB patients in South Africa.

There is scant detail, however an Indian biotechnology company says it is bringing out a TB vaccine and will sign a MoU with another firm for necessary technology.

The three most common potentially fatal fungal infections - cryptococcal meningitis, Pneumocystis pneumonia and Histoplasma - far outnumber TB cases in HIV patients, especially when some reported 'TB cases' are not TB at all. More people probably die of fungal disease than of TB, both in the context of AIDS and generally. Source: The Conversation

The TB Alliance Stakeholders’ Association annual meeting ( video recording here ), on 17 February, provided updates on a range of important topics for us, including:
An update on BPaL regimen trials
BPaL research in the Ukraine.

Scientists in Chicago, US, report accurate and rapid predictions of TB drug resistance from genome sequence data using traditional machine learning algorithms and convolutional neural network methods.

Two weeks makes a big difference in treating the animal version of HIV and latent TB, researchers in the US find. It’s predicted that this knowledge can assist in developing therapies and a combined vaccine for the two diseases in humans.

In a bid to understand more about drug-resistant TB, researchers analysed thousands of changes found in three different micro-organisms, including bacteria that cause TB.

This research finds integrating the screening of non-communicable diseases and their risk factors during TB assessment for early diagnosis, treatment initiation and chronic care management should be implemented in all TB care facilities.

Researchers find the families of MDR-TB patients are at risk of infection from the same type of drug-resistant TB.

A new TB modelling study from the London School of Hygiene and Tropical Medicine estimated the potential health impact and cost-effectiveness of the new TB vaccine M72/AS01E in two high TB burden countries: India and South Africa.

According to results of a study published in Thorax, treatment with high-dose rifamycin-based regimens was not associated with an increased risk for severe adverse events compared with standard-dose rifamycin-based regimens among patients with TB.